Key result
Different diets in chronic T. cruzi-infected mice altered serum metabolomic profiles, identifying cardiac ventricular-specific metabolite biomarkers that could define Chagas cardiomyopathy severity.
Why the study?
Factors responsible for the transition from the asymptomatic indeterminate latent stage of T. cruzi infection to chronic Chagas cardiomyopathy are poorly understood, and biomarkers are needed to identify patients at higher risk.
Diet-induced metabolic changes in a murine model of Chagas disease alter serum metabolomic profiles, identifying potential biomarkers for predicting the risk of developing chronic Chagas cardiomyopathy.
Hypothesis-generating in murine models; leaves open human validation of metabolite biomarkers for Chagas cardiomyopathy risk.
Chagas disease is caused by Trypanosoma cruzi which is endemic in Latin America. T. cruzi infection results in a latent infection with approximately a third of latently infected patients developing chronic Chagas cardiomyopathy (CCM). CCM is a common cause of cardiomyopathy in endemic regions and has a poor prognosis compared to other cardiomyopathies. The factors responsible for the transition from the asymptomatic indeterminate latent stage of infection to CCM are poorly understood. Our previous studies demonstrated that lipid metabolism and diet are important determinants of disease progression. In the present study, we analyzed various serum metabolomic biomarkers such as acylcarnitines, amino acids, biogenic amines, glycerophospholipids, and sphingolipids in murine models of CCM, where the mice specifically develop either left or right ventricular cardiomyopathy based on the diets fed during the indeterminate stage in a murine model of Chagas disease. Our data provide new insights into the metabolic changes that may predispose patients to CCM and biomarkers that may help predict the risk of developing cardiomyopathy from T. cruzi infection. Author Summary. Chronic Chagas cardiomyopathy (CCM) is a parasitic disease prevalent in Latin America. Currently, no effective drugs or vaccines are available to prevent or cure CCM. The factors involved in the disease severity and progression are poorly understood to design new therapeutic interventions. In order to rapidly identify Chagas patients with a higher risk to develop CCM, a new set of biomarkers specific to Chagas disease is needed. We performed serum metabolomic analyses in chronic T. cruzi-infected mice fed on different diets and identified cardiac ventricular-specific metabolite biomarkers that could define CCM severity. In this paper, we present the results of serum metabolomic analyses and discuss its correlations to the diet-induced metabolic regulations in the pathogenesis of CCM in a murine model of Chagas disease.
No takes yet. Share an insight, caveat, or question.
Lizardo et al. (2019) studied Chronic Chagas cardiomyopathy. Different diets was evaluated on Serum metabolomic biomarkers (acylcarnitines, amino acids, biogenic amines, glycerophospholipids, and sphingolipids). Different diets in chronic T. cruzi-infected mice altered serum metabolomic profiles, identifying cardiac ventricular-specific metabolite biomarkers that could define Chagas cardiomyopathy severity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: